Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 8Brain Neoplasms 5Neoplasms 4Glioma 3Medulloblastoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Ketosis 1Insulin Resistance 1Gliosarcoma 1Diabetes Mellitus 1Colonic Neoplasms 1Cognitive Dysfunction 1Chondrosarcoma 1Cholangiocarcinoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 4Nivolumab 3Gemcitabine 3Fluorodeoxyglucose F18 3olutasidenib 2olaparib 2durvalumab 2Specimen Handling 2FAPI-46 2Cisplatin 2ulixertinib 1pembrolizumab 1ivosidenib 1entrectinib 1enasidenib 1cobimetinib 1alectinib 1Topotecan 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Metformin 1Ipilimumab 1Immunotherapy 1Folfox protocol 1Fluoresceins 1Fluorescein 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Metformin × CNS × Clear all
NCT02496741 2020-01-09

MACIST

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Completed
15 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡